AIP
PHAS

Ameritas Investment Partners’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Ameritas Investment Partners’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,211
Closed -$4K – 3312
2021
Q1 		$4K Hold
1,211
– – ﹤0.01% 3047
2020
Q4 		$4K Hold
1,211
– – ﹤0.01% 3015
2020
Q3 		$4K Hold
1,211
– – ﹤0.01% 3030
2020
Q2 		$6K Hold
1,211
– – ﹤0.01% 2938
2020
Q1 		$4K Hold
1,211
– – ﹤0.01% 2886
2019
Q4 		$7K Hold
1,211
– – ﹤0.01% 2860
2019
Q3 		$5K Hold
1,211
– – ﹤0.01% 2948
2019
Q2 		$16K Buy
+1,211
New +$14.8K ﹤0.01% 2594

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Ameritas Investment Partners's PHAS Position: Q2 2021 in Review

Ameritas Investment Partners sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 1,211 shares — an estimated $4K sold.

Ameritas Investment Partners first reported a position in PHAS in Q2 2019 and held it in 8 quarters. The position peaked at $16K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

  • Ameritas Investment Partners reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,211 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $4K.
  • Ameritas Investment Partners first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Ameritas Investment Partners's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $16K in Q2 2019.
  • 55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.